TY  - JOUR
AU  - Vranić-Mandušić, Vesna
AU  - Subota, Vesna
AU  - Savovski, K
AU  - Medic, L
AU  - Dramićanin, Tatjana
AU  - Jozanov-Stankov, Olga
AU  - Popov-Celeketic, D
AU  - Jokanović, Milan
AU  - Dimitrijević, Bogomir B.
PY  - 2004
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2701
AB  - Tiazofurin (TZF) is a cytostatic drug that leads to depletion of the GTP pool in tumor and normal cells via its active metabolite tiazofurin-adenine dinucleotide (TAD). TAD was detected in different cell lines, but not in erythrocytes, so the mechanism of erythrocytotoxicity of TZF remains unclear. The purpose of this study was to evaluate in vitro and in vivo action of tiazofurin on rat erythrocytes (RBC). After two decades of clinical trials the question of erythrocytotoxicity of TZF had remained unexplained making this study justified. Since we have previously demonstrated early erythrocytotoxic effects in male Wistar rats, we extend this finding on isolated RBC. Isolated erythrocytes from untreated animals were treated in buffered solution or plasma containing TZF In addition, groups of 10 rats were treated with 200 and 1000 mg/kg of TZF and hematologic parameters were analyzed by flowcytometry and by the analysis of the peripheral blood smears. Early signs of hemolysis or aberrant structures were monitored by scanning probe microscopy (SPM). We suggest that correlation exists between early erythrocytotoxicity and irregularities in erythrocyte morphology and membrane integrity. We also found that TZF affects responsiveness to oxidative stress. This is in concordance with flowcytometric findings describing anisocytosis and anisochromosis of RBC. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
T2  - Toxicology Letters
T1  - Erythrocytotoxicity of tiazofurin in vivo and in vitro detected by scanning probe microscopy
VL  - 146
IS  - 3
SP  - 275
EP  - 284
DO  - 10.1016/j.toxlet.2003.10.013
ER  - 

@article{
author = "Vranić-Mandušić, Vesna and Subota, Vesna and Savovski, K and Medic, L and Dramićanin, Tatjana and Jozanov-Stankov, Olga and Popov-Celeketic, D and Jokanović, Milan and Dimitrijević, Bogomir B.",
year = "2004",
abstract = "Tiazofurin (TZF) is a cytostatic drug that leads to depletion of the GTP pool in tumor and normal cells via its active metabolite tiazofurin-adenine dinucleotide (TAD). TAD was detected in different cell lines, but not in erythrocytes, so the mechanism of erythrocytotoxicity of TZF remains unclear. The purpose of this study was to evaluate in vitro and in vivo action of tiazofurin on rat erythrocytes (RBC). After two decades of clinical trials the question of erythrocytotoxicity of TZF had remained unexplained making this study justified. Since we have previously demonstrated early erythrocytotoxic effects in male Wistar rats, we extend this finding on isolated RBC. Isolated erythrocytes from untreated animals were treated in buffered solution or plasma containing TZF In addition, groups of 10 rats were treated with 200 and 1000 mg/kg of TZF and hematologic parameters were analyzed by flowcytometry and by the analysis of the peripheral blood smears. Early signs of hemolysis or aberrant structures were monitored by scanning probe microscopy (SPM). We suggest that correlation exists between early erythrocytotoxicity and irregularities in erythrocyte morphology and membrane integrity. We also found that TZF affects responsiveness to oxidative stress. This is in concordance with flowcytometric findings describing anisocytosis and anisochromosis of RBC. (C) 2003 Elsevier Ireland Ltd. All rights reserved.",
journal = "Toxicology Letters",
title = "Erythrocytotoxicity of tiazofurin in vivo and in vitro detected by scanning probe microscopy",
volume = "146",
number = "3",
pages = "275-284",
doi = "10.1016/j.toxlet.2003.10.013"
}

Vranić-Mandušić, V., Subota, V., Savovski, K., Medic, L., Dramićanin, T., Jozanov-Stankov, O., Popov-Celeketic, D., Jokanović, M.,& Dimitrijević, B. B.. (2004). Erythrocytotoxicity of tiazofurin in vivo and in vitro detected by scanning probe microscopy. in Toxicology Letters, 146(3), 275-284.
https://doi.org/10.1016/j.toxlet.2003.10.013

Vranić-Mandušić V, Subota V, Savovski K, Medic L, Dramićanin T, Jozanov-Stankov O, Popov-Celeketic D, Jokanović M, Dimitrijević BB. Erythrocytotoxicity of tiazofurin in vivo and in vitro detected by scanning probe microscopy. in Toxicology Letters. 2004;146(3):275-284.
doi:10.1016/j.toxlet.2003.10.013 .

Vranić-Mandušić, Vesna, Subota, Vesna, Savovski, K, Medic, L, Dramićanin, Tatjana, Jozanov-Stankov, Olga, Popov-Celeketic, D, Jokanović, Milan, Dimitrijević, Bogomir B., "Erythrocytotoxicity of tiazofurin in vivo and in vitro detected by scanning probe microscopy" in Toxicology Letters, 146, no. 3 (2004):275-284,
https://doi.org/10.1016/j.toxlet.2003.10.013 . .

TY  - JOUR
AU  - Ivanović, Vesna
AU  - Todorović-Raković, N
AU  - Demajo, Miroslav
AU  - Nešković-Konstantinović, Zora
AU  - Subota, Vesna
AU  - Ivanišević-Milovanović, Olivera
AU  - Nikolić-Vukosavljević, Dragica
PY  - 2003
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2617
AB  - We examined the association between an elevated plasma TGF-beta(1) level and the disease progression of advanced breast cancer (BC) patients (n = 44). TGF-beta(1) levels were detected by an enzyme-linked immunosorbent assay (ELISA). Platelet carryover and in vitro platelet activation in our plasma samples was assessed and found to be insignificant. Plasma TGF-beta(1) values were significantly elevated (P LT 0.05) in stage IIIB/IV patients (median value: 2.40 ng/ml, range: 0.13-8.48 ng/ml, n=44) compared with healthy donors (median value: 1.30 ng/ml, range: 0.41-4.93 ng/ml, n=36). Although pronounced in metastatic patients, especially those who had been newly diagnosed, TGF- and beta;(1) elevation was independent of tumour mass, site of distant metastases, histopathological type, steroid receptor (SR) content and age of the BC patients. Follow-up of 6 patients indicated a relationship between the plasma TGF- and beta;(1) and the patients response. This suggests that TGF- and beta;(1), may be a promising prognostic marker for breast cancer patients with advanced disease. Confirmatory large-scale studies are needed, particularly given the overlap of values between our different subgroups analysed.
T2  - European Journal of Cancer
T1  - Elevated plasma levels of transforming growth factor-beta(1) (TGF-beta(1)) in patients with advanced breast cancer: association with disease progression
VL  - 39
IS  - 4
SP  - 454
EP  - 461
DO  - 10.1016/S0959-8049(02)00502-6
ER  - 

@article{
author = "Ivanović, Vesna and Todorović-Raković, N and Demajo, Miroslav and Nešković-Konstantinović, Zora and Subota, Vesna and Ivanišević-Milovanović, Olivera and Nikolić-Vukosavljević, Dragica",
year = "2003",
abstract = "We examined the association between an elevated plasma TGF-beta(1) level and the disease progression of advanced breast cancer (BC) patients (n = 44). TGF-beta(1) levels were detected by an enzyme-linked immunosorbent assay (ELISA). Platelet carryover and in vitro platelet activation in our plasma samples was assessed and found to be insignificant. Plasma TGF-beta(1) values were significantly elevated (P LT 0.05) in stage IIIB/IV patients (median value: 2.40 ng/ml, range: 0.13-8.48 ng/ml, n=44) compared with healthy donors (median value: 1.30 ng/ml, range: 0.41-4.93 ng/ml, n=36). Although pronounced in metastatic patients, especially those who had been newly diagnosed, TGF- and beta;(1) elevation was independent of tumour mass, site of distant metastases, histopathological type, steroid receptor (SR) content and age of the BC patients. Follow-up of 6 patients indicated a relationship between the plasma TGF- and beta;(1) and the patients response. This suggests that TGF- and beta;(1), may be a promising prognostic marker for breast cancer patients with advanced disease. Confirmatory large-scale studies are needed, particularly given the overlap of values between our different subgroups analysed.",
journal = "European Journal of Cancer",
title = "Elevated plasma levels of transforming growth factor-beta(1) (TGF-beta(1)) in patients with advanced breast cancer: association with disease progression",
volume = "39",
number = "4",
pages = "454-461",
doi = "10.1016/S0959-8049(02)00502-6"
}

Ivanović, V., Todorović-Raković, N., Demajo, M., Nešković-Konstantinović, Z., Subota, V., Ivanišević-Milovanović, O.,& Nikolić-Vukosavljević, D.. (2003). Elevated plasma levels of transforming growth factor-beta(1) (TGF-beta(1)) in patients with advanced breast cancer: association with disease progression. in European Journal of Cancer, 39(4), 454-461.
https://doi.org/10.1016/S0959-8049(02)00502-6

Ivanović V, Todorović-Raković N, Demajo M, Nešković-Konstantinović Z, Subota V, Ivanišević-Milovanović O, Nikolić-Vukosavljević D. Elevated plasma levels of transforming growth factor-beta(1) (TGF-beta(1)) in patients with advanced breast cancer: association with disease progression. in European Journal of Cancer. 2003;39(4):454-461.
doi:10.1016/S0959-8049(02)00502-6 .

Ivanović, Vesna, Todorović-Raković, N, Demajo, Miroslav, Nešković-Konstantinović, Zora, Subota, Vesna, Ivanišević-Milovanović, Olivera, Nikolić-Vukosavljević, Dragica, "Elevated plasma levels of transforming growth factor-beta(1) (TGF-beta(1)) in patients with advanced breast cancer: association with disease progression" in European Journal of Cancer, 39, no. 4 (2003):454-461,
https://doi.org/10.1016/S0959-8049(02)00502-6 . .